NEW YORK, June 3, 2026, 17:06 (EDT)
- Mirion finished the session 1.1% higher at $18.24, holding gains while the main U.S. indexes slipped.
- Company updates from June 2 focused on its nuclear franchise. The company also mentioned its partnership with the University of Liverpool.
- First-quarter orders and revenue are still the main proof, and earnings guidance is still a constraint.
Mirion Technologies Inc. shares gained Wednesday. The stock moved higher even as U.S. markets slipped. Investors stayed focused on Mirion’s nuclear-safety angle after recent company news, instead of following the broader risk-off trend.
The stock settled at $18.24, up 20 cents, or 1.1%. During the session, it traded between $17.91 and $18.65. About 4.64 million shares changed hands, topping the 4.24 million average. It held steady after hours at $18.25.
Stocks slipped as the market turned weaker. The S&P 500 dropped 0.74%, the Dow slid 1.21% and the Nasdaq lost 0.89%. Oil prices climbed and Wall Street gave up ground after hitting records. Wasif Latif, chief investment officer at Sarmaya Partners, told Reuters the market was “taking a breather.” Reuters
Mirion isn’t a major index name. Still, as industrial tech names have found favor, the stock’s gain on a weak day prompts some traders to look again at the Atlanta firm’s work in radiation detection, nuclear safety and cancer-care quality gear.
Mirion said June 2 that the University of Liverpool has signed a memorandum of understanding to expand its collaboration with the company on nuclear science, radiation protection and other strategic tech. Mirion called it its first agreement of this type with a UK university.
James Cocks, chief technology officer at Mirion, said in the statement: “There is no path to advancing nuclear capability without strong collaboration.” Investors are likely to see the comment in light of the company’s main question—if growing nuclear activity can mean steady orders.
Mirion said June 2 that Tighe Smith, its chief nuclear officer and also Paragon Energy Solutions’ chief nuclear officer, got an American Nuclear Society Presidential Citation at the group’s annual meeting. According to Mirion, Smith runs global nuclear strategy for both Paragon and Mirion.
Larger players in instrumentation and scientific equipment traded mixed. Thermo Fisher Scientific dropped 1.7%, Teledyne Technologies inched down 0.1%. Ametek gained 0.3%. The moves suggest that Mirion’s action doesn’t amount to a broad bid across the whole measurement-equipment group.
Mirion’s first-quarter numbers are in for the April quarter. The company reported revenue up 27.5% at $257.6 million. Orders were up 19% if you back out Paragon and Certrec. Adjusted EBITDA gained 16.3% to $54.3 million. CEO Thomas Logan said there was “substantial orders growth led by nuclear power demand.” Mirion Technologies, Inc.
The story isn’t all positive. Mirion posted a GAAP net loss of $3.4 million and lowered its adjusted EPS guidance to $0.48-$0.55 from $0.50-$0.57, citing a one-time retention grant for its CEO. If nuclear orders don’t turn into cash flow, or if higher rates and oil-fueled inflation hit smaller industrial stocks, Wednesday’s rally may not last.
For now, the stock’s story is straightforward. Investors ignored the weak market and stayed with Mirion in nuclear safety. The question ahead is if those orders turn up in margins instead of just announcements.
